Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Abstract 834: In vivo, ex vivo, and in vitro (2D and 3D) tumor models: Uses, strengths and limitations

Beverly A. Teicher, Melinda G. Hollingshead, Nathan P. Coussens, Thomas S. Dexheimer, Thomas E. Silvers, Eric M. Jones, Larry Rubinstein, James H. Doroshow

Cancer Res (2025) 85 (8_Supplement_1): 834.

https://doi.org/10.1158/1538-7445.AM2025-834

Published: 21 April 2025

View articletitled, Abstract 834: In vivo, ex vivo, and in vitro (2D and 3D) tumor models: Uses, strengths and limitations

Journal Articles

Abstract CT194: ETCTN 10388: a first in human phase I trial of triapine and lutetium Lu 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Cancer Res (2023) 83 (8_Supplement): CT194.

https://doi.org/10.1158/1538-7445.AM2023-CT194

Published: 14 April 2023

View articletitled, Abstract CT194: ETCTN 10388: a first in human phase I trial of triapine and lutetium Lu 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Journal Articles

Abstract CT115: Safety and efficacy of Anti-PD-L1 antibody MEDI4736 (durvalumab) in combination with capecitabine in patients with advanced solid tumors (DURVA+)

Mohamad Adham Salkeni, Geraldine O’Sullivan Coyne, Naoko Takebe, Elad Sharon, Howard Streicher, Jessica Mukherjee, Ashley Bruns, Arjun Mitra, Abdul R. Naqash, Larry Rubinstein, Kristin K. Fino, King L. Fung, Katherine Ferry-Galow, Ralph Parchment, Helen Chen, James Doroshow, Alice Chen

Cancer Res (2022) 82 (12_Supplement): CT115.

https://doi.org/10.1158/1538-7445.AM2022-CT115

Published: 15 June 2022

View articletitled, Abstract CT115: Safety and efficacy of Anti-PD-L1 antibody MEDI4736 (durvalumab) in combination with capecitabine in patients with advanced solid tumors (DURVA+)

Journal Articles

Abstract CT147: Phase 1 study of recombinant interleukin 15 (rhIL-15) in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers

Sarah J. Shin, Geraldine O'Sullivan Coyne, Howard Streicher, Naoko Takebe, Ashley Bruns, Elad Sharon, Richard Piekarz, Lamin Juwara, Larry Rubinstein, Ralph Parchment, Kristin Fino, King L. Fung, Katherine Ferry-Galow, Arjun Mittra, Abdul Rafeh Naqash, Kevin Conlon, James H. Doroshow, Alice P. Chen

Cancer Res (2022) 82 (12_Supplement): CT147.

https://doi.org/10.1158/1538-7445.AM2022-CT147

Published: 15 June 2022

View articletitled, Abstract CT147: Phase 1 study of recombinant interleukin 15 (rhIL-15) in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers

Journal Articles

Abstract CT138: Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors, lymphomas, or myelodysplastic syndromes

James Q. Nguyen, Geraldine O'Sullivan Coyne, Larry Rubinstein, Shivaani Kummar, Lamin Juwara, Jennifer Zlott, Abdul Rafeh Naqash, Murielle Hogu, Jerry Collins, Apurva Srivastava, Brandon Miller, Ralph E. Parchment, Robert Meehan, Christopher S. Hourigan, Steven Pavletic, James H. Doroshow, Alice P. Chen, Naoko Takebe

Cancer Res (2021) 81 (13_Supplement): CT138.

https://doi.org/10.1158/1538-7445.AM2021-CT138

Published: 01 July 2021

View articletitled, Abstract CT138: Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors, lymphomas, or myelodysplastic syndromes

Journal Articles

Abstract LB-107: TET2/DNMT3A mutations and exceptional response to novel epigenetic agent in human malignancies

Sherry X. Yang, Larry Rubinstein, Dat Nguyen, Angelo B. Larenjeira, Robert Kinders, Michael Difilippantonio, James H. Doroshow

Cancer Res (2020) 80 (16_Supplement): LB-107.

https://doi.org/10.1158/1538-7445.AM2020-LB-107

Published: 15 August 2020

View articletitled, Abstract LB-107: TET2/DNMT3A mutations and exceptional response to novel epigenetic agent in human malignancies

Journal Articles

Abstract CT061: Binimetinib in patients with tumors with NRAS mutations: NCI-MATCH ECOG-ACRIN Cancer Research Group subprotocol EAY131-Z1A

Cancer Res (2020) 80 (16_Supplement): CT061.

https://doi.org/10.1158/1538-7445.AM2020-CT061

Published: 15 August 2020

View articletitled, Abstract CT061: Binimetinib in patients with tumors with NRAS mutations: NCI-MATCH ECOG-ACRIN Cancer Research Group subprotocol EAY131-Z1A

Journal Articles

Abstract CT099: DNA damage response and therapeutic activity following once-daily administration of the Wee 1 inhibitor AZD1775 (adavosertib)

Cancer Res (2019) 79 (13_Supplement): CT099.

https://doi.org/10.1158/1538-7445.AM2019-CT099

Published: 01 July 2019

View articletitled, Abstract CT099: DNA damage response and therapeutic activity following once-daily administration of the Wee 1 inhibitor AZD1775 (adavosertib)

Journal Articles

Abstract 3847: Knockout of DNMT1 using CRISPR gene-editing technology confers resistance to DNMT inhibitors in human breast cancer cells

Angelo B. Laranjeira, Erich Huang, Larry Rubinstein, Dat Nguyen, Sherry X. Yang

Cancer Res (2019) 79 (13_Supplement): 3847.

https://doi.org/10.1158/1538-7445.AM2019-3847

Published: 01 July 2019

View articletitled, Abstract 3847: Knockout of DNMT1 using CRISPR gene-editing technology confers resistance to DNMT inhibitors in human breast cancer cells

Journal Articles

Abstract 986: The National Cancer Institute's patient-derived models repository (PDMR)

Yvonne A. Evrard, Michelle M. Gottholm Ahalt, Sergio . Y. Alcoser, Kaitlyn Arthur, Mariah Baldwin, Linda L. Blumenauer, Carrie Bonomi, Suzanne Borgel, Elizabeth Bradtke, Corinne Camalier, John Carter, Tiffanie Chase, Alice Chen, Lily Chen, Donna W. Coakley, Nicole E. Craig, Biswajit Das, Vivekananda Datta, Jordyn Davidson, Margaret R. DeFreytas, Emily Delaney, Michelle A. Eugeni, Raymond Divelbiss, Palmer Fliss, Thomas Forbes, Marion Gibson, Tara Grinnage-Pulley, Sierra Hoffman, Lilia Ileva, Paula Jacobs, Franklyn Jimenez, Joseph Kalen, Catherine Karangwa, Chris Karlovich, Candace Mallow, Chelsea McGlynn, Jenna E. Moyer, Michael Mullendore, Dianne L. Newton, Nimit Patel, Rajesh Patidar, Kevin Plater, Marianne Radzyminski, Lisa Riffle, Larry Rubinstein, Luke H. Stockwin, Mickey Williams, Melinda G. Hollingshead, James H. Doroshow

Cancer Res (2018) 78 (13_Supplement): 986.

https://doi.org/10.1158/1538-7445.AM2018-986

Published: 01 July 2018

View articletitled, Abstract 986: The National Cancer Institute's patient-derived models repository (PDMR)

Journal Articles

The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity

Susan L. Holbeck, Richard Camalier, James A. Crowell, Jeevan Prasaad Govindharajulu, Melinda Hollingshead, Lawrence W. Anderson, Eric Polley, Larry Rubinstein, Apurva Srivastava, Deborah Wilsker, Jerry M. Collins, James H. Doroshow

Cancer Res (2017) 77 (13): 3564–3576.

https://doi.org/10.1158/0008-5472.CAN-17-0489

Published: 01 July 2017

View articletitled, The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity

Includes: Supplementary data

Journal Articles

Abstract 3840: The National Cancer Institute’s patient-derived models repository (PDMR)

Cancer Res (2017) 77 (13_Supplement): 3840.

https://doi.org/10.1158/1538-7445.AM2017-3840

Published: 01 July 2017

View articletitled, Abstract 3840: The National Cancer Institute’s patient-derived models repository (PDMR)

Journal Articles

Abstract 4722: Selective inhibition of DNA methyltransferases and efficacy of novel DNMT inhibitors in leukemia xenografts

Dat Nguyen, Melinda Hollingshead, Larry Rubinstein, James Doroshow, Sherry X. Yang

Cancer Res (2016) 76 (14_Supplement): 4722.

https://doi.org/10.1158/1538-7445.AM2016-4722

Published: 15 July 2016

View articletitled, Abstract 4722: Selective inhibition of DNA methyltransferases and efficacy of novel DNMT inhibitors in leukemia xenografts

Journal Articles

Abstract CT101: NCI-molecular analysis for therapy choice (NCI-MATCH) clinical trial: interim analysis

Barbara A. Conley, Robert Gray, Alice Chen, Peter O’Dwyer, Carlos Arteaga, Brent Coffey, David Patton, Shuli Li, Lisa M. McShane, Larry Rubinstein, Robert Comis, Jeffrey Abrams, Paul M. Williams, Chih-Jian Lih, Stanley Hamilton, Edith Mitchell, James Zwiebel, Keith Flaherty, NCI MATCH team

Cancer Res (2016) 76 (14_Supplement): CT101.

https://doi.org/10.1158/1538-7445.AM2016-CT101

Published: 15 July 2016

View articletitled, Abstract CT101: NCI-molecular analysis for therapy choice (NCI-MATCH) clinical trial: interim analysis

Journal Articles

Abstract P2-18-02: Characteristics and outcome of breast cancer patients enrolled in cancer therapy evaluation program (CTEP) sponsored phase I clinical trials

Filipa Lynce, Larry Rubinstein, Pamela Harris

Cancer Res (2015) 75 (9_Supplement): P2-18-02.

https://doi.org/10.1158/1538-7445.SABCS14-P2-18-02

Published: 01 May 2015

View articletitled, Abstract P2-18-02: Characteristics and outcome of breast cancer patients enrolled in cancer therapy evaluation program (CTEP) sponsored phase I clinical trials

Journal Articles

Abstract 3838: Differential expression of Notch1 in lung, ovarian and breast cancers

Dat Nguyen, Larry Rubinstein, Mark E. Sherman, Joseph E. Tomaszewski, Naoko Takebe, Percy Ivy, James H. Doroshow, Sherry X. Yang

Cancer Res (2014) 74 (19_Supplement): 3838.

https://doi.org/10.1158/1538-7445.AM2014-3838

Published: 01 October 2014

View articletitled, Abstract 3838: Differential expression of Notch1 in lung, ovarian and breast cancers

Journal Articles

Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas

Cancer Res (2011) 71 (17): 5626–5634.

https://doi.org/10.1158/0008-5472.CAN-11-1227

Published: 30 August 2011

View articletitled, Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas

Includes: Supplementary data

Journal Articles

Abstract 3637: Sensitivity of breast cancer cell lines with distinct genotypes to poly(ADP-ribose) polymerase inhibitor or in combination with DNA damaging agents

Diana Nguyen, Larry Rubinstein, Joseph E. Tomaszewski, Shivaani Kummar, James H. Doroshow, Sherry X. Yang

Cancer Res (2010) 70 (8_Supplement): 3637.

https://doi.org/10.1158/1538-7445.AM10-3637

Published: 15 April 2010

View articletitled, Abstract 3637: Sensitivity of breast cancer cell lines with distinct genotypes to poly(ADP-ribose) polymerase inhibitor or in combination with DNA damaging agents

Journal Articles

Abstract #4701: UCN-01 significantly enhances anti-cancer activity of poly(ADP-ribose) polymerase inhibition in combination with DNA damaging agent

Dat Nguyen, Maria Zajac-Kaye, Donna Voeller, Larry Rubinstein, Joseph Tomaszewski, Shivaani Kummar, Yves Pommier, James Doroshow, Sherry Yang

Cancer Res (2009) 69 (9_Supplement): 4701.

Published: 01 May 2009

View articletitled, Abstract #4701: UCN-01 significantly enhances anti-cancer activity of poly(ADP-ribose) polymerase inhibition in combination with DNA damaging agent

Journal Articles

Abstract #5456: Correlation between inhibition of the activity of poly(ADP-ribose) polymerase (PARP) in human peripheral blood mononuclear cells (PBMCs) and tumor biopsies following treatment with ABT-888, an inhibitor of PARP

Shivaani Kummar, Larry Rubinstein, Robert Kinders, Jiuping Ji, Ralph Parchment, Martin Gutierrez, Anthony Murgo, Alice Chen, Sonny Khin, Yiping Zhang, Dwight Simmons, Mary Ann Yancey, Deborah Allen, Yvonne Horneffer, Lamin Juwara, Richard Chang, Gary Gordon, Joseph Tomaszewski, James Doroshow

Cancer Res (2009) 69 (9_Supplement): 5456.

Published: 01 May 2009

View articletitled, Abstract #5456: Correlation between inhibition of the activity of poly(ADP-ribose) polymerase (PARP) in human peripheral blood mononuclear cells (PBMCs) and tumor biopsies following treatment with ABT-888, an inhibitor of PARP

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 834: In vivo, ex vivo, and in vitro (2D and 3D) tumor models: Uses, strengths and limitations

Abstract CT194: ETCTN 10388: a first in human phase I trial of triapine and lutetium Lu 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Abstract CT115: Safety and efficacy of Anti-PD-L1 antibody MEDI4736 (durvalumab) in combination with capecitabine in patients with advanced solid tumors (DURVA+)

Abstract CT147: Phase 1 study of recombinant interleukin 15 (rhIL-15) in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers

Abstract CT138: Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors, lymphomas, or myelodysplastic syndromes

Abstract LB-107: TET2/DNMT3A mutations and exceptional response to novel epigenetic agent in human malignancies

Abstract CT061: Binimetinib in patients with tumors with NRAS mutations: NCI-MATCH ECOG-ACRIN Cancer Research Group subprotocol EAY131-Z1A

Abstract CT099: DNA damage response and therapeutic activity following once-daily administration of the Wee 1 inhibitor AZD1775 (adavosertib)

Abstract 3847: Knockout of DNMT1 using CRISPR gene-editing technology confers resistance to DNMT inhibitors in human breast cancer cells

Abstract 986: The National Cancer Institute's patient-derived models repository (PDMR)

The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity

Abstract 3840: The National Cancer Institute’s patient-derived models repository (PDMR)

Abstract 4722: Selective inhibition of DNA methyltransferases and efficacy of novel DNMT inhibitors in leukemia xenografts

Abstract CT101: NCI-molecular analysis for therapy choice (NCI-MATCH) clinical trial: interim analysis

Abstract P2-18-02: Characteristics and outcome of breast cancer patients enrolled in cancer therapy evaluation program (CTEP) sponsored phase I clinical trials

Abstract 3838: Differential expression of Notch1 in lung, ovarian and breast cancers

Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas

Abstract 3637: Sensitivity of breast cancer cell lines with distinct genotypes to poly(ADP-ribose) polymerase inhibitor or in combination with DNA damaging agents

Abstract #4701: UCN-01 significantly enhances anti-cancer activity of poly(ADP-ribose) polymerase inhibition in combination with DNA damaging agent

Abstract #5456: Correlation between inhibition of the activity of poly(ADP-ribose) polymerase (PARP) in human peripheral blood mononuclear cells (PBMCs) and tumor biopsies following treatment with ABT-888, an inhibitor of PARP

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only